Clinical Trials
13 trialsNCT03587740 2026-05-18
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06663787 2026-05-13
HER2 CR
Nagoya City University
Active not recruiting
NCT06595563 2026-05-07
ZEPHIR-02
Jules Bordet Institute
Phase 2 Recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT02314481 2026-05-04
DARWINII
University College, London
Phase 2 Completed
NCT05408845 2026-05-04
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting
NCT04733118 2026-04-29
PHERGAIN-2
MedSIR
Phase 2 Active not recruiting
NCT04893109 2026-04-24
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT02326974 2026-04-17
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04620187 2026-04-13
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT02390427 2026-04-09
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT05323955 2026-03-17
BRIDGET
Duke University
Phase 2 Active not recruiting